Ok, always make sure you're in comparison shopping to ensure you're getting the best deal and be sure to leverage any ...
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended ...
Researchers at University of California San Francisco (UCSF) have developed a single genomic test that can quickly detect ...
Understanding genetic risks of prostate cancer can help individuals take proactive steps to protect their health.
There’s a local program called the Gene Health Project, and the idea is to learn any bad genetic news about yourself but ...
You don’t have to wait for Walmart’s actual Black Friday sale: These stellar discounts on Wirecutter-approved products are ...
NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics ...
The restructuring arrives during a period of turmoil at South San Francisco-based 23andMe, which has recently included a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback